NASDAQ:ELYM Eliem Therapeutics (ELYM) Stock Price, News & Analysis $7.86 +0.47 (+6.36%) (As of 10:43 AM ET) Add Compare Share Share Today's Range$7.20▼$7.9250-Day Range$5.81▼$8.9352-Week Range$2.35▼$11.55Volume111,910 shsAverage Volume418,469 shsMarket Capitalization$527.09 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Eliem Therapeutics alerts: Email Address Ad Porter & CompanyThe only AI company to buyThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About Eliem Therapeutics Stock (NASDAQ:ELYM)Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Read More ELYM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELYM Stock News HeadlinesAugust 26, 2024 | globenewswire.comEliem Therapeutics Announces Additions to its Leadership TeamAugust 14, 2024 | globenewswire.comEliem Therapeutics Reports Second Quarter Financial ResultsSeptember 9, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.July 24, 2024 | finance.yahoo.comInsider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells SharesJuly 22, 2024 | benzinga.comIQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On MondayJuly 19, 2024 | sg.finance.yahoo.comInsider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ...July 19, 2024 | finance.yahoo.comEVP, R&D AND CSO Valerie Morisset Sells 50,000 Shares of Eliem Therapeutics Inc (ELYM)June 28, 2024 | globenewswire.comEliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® IndexesSeptember 9, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.June 27, 2024 | globenewswire.comEliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private PlacementMay 17, 2024 | benzinga.comEliem Therapeutics Stock (NASDAQ:ELYM), Earnings Estimates, EPS, and RevenueApril 15, 2024 | prnewswire.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the FirmApril 12, 2024 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private PlacementApril 11, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODNApril 11, 2024 | finance.yahoo.comEliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines DealApril 11, 2024 | msn.comEnlivex Therapeutics, Nyxoah SA, China SXT Pharmaceuticals among healthcare moversApril 11, 2024 | markets.businessinsider.comEliem Therapeutics To Buy Tenet Medicines, Plans $120 Mln Private Placement; Stock Up In Pre-marketApril 11, 2024 | businesswire.comELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to ShareholdersSee More Headlines Receive ELYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/09/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELYM CUSIPN/A CIK1768446 Webwww.eliemtx.com Phone877-354-3689FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.03% Return on Assets-45.97% Debt Debt-to-Equity RatioN/A Current Ratio60.41 Quick Ratio60.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.90 per share Price / Book2.02Miscellaneous Outstanding Shares67,060,000Free Float28,354,000Market Cap$527.09 million OptionableNot Optionable Beta-0.35 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Andrew Levin M.D. (Age 46)Ph.D., Principal Financial Officer & Executive Chairman Comp: $73kDr. Valerie Morisset Ph.D. (Age 54)Chief Scientific Officer and Executive VP of Research & Development Comp: $617.87kMs. Emily Pimblett (Age 40)Principal Accounting Officer Ms. Jo Palmer-Phillips Ph.D.Chief Development OfficerKey CompetitorsXBiotechNASDAQ:XBITCompugenNASDAQ:CGENSelecta BiosciencesNASDAQ:SELBMarinus PharmaceuticalsNASDAQ:MRNSEnochian BiosciencesNASDAQ:ENOBView All CompetitorsInsiders & InstitutionsDriehaus Capital Management LLCSold 115,623 shares on 8/16/2024Ownership: 2.340%Affinity Asset Advisors LLCBought 1,670,661 shares on 8/15/2024Ownership: 5.615%Ally Bridge Group NY LLCBought 500,000 shares on 8/14/2024Ownership: 1.681%Renaissance Technologies LLCBought 26,383 shares on 8/9/2024Ownership: 0.124%Dimensional Fund Advisors LPBought 12,560 shares on 8/9/2024Ownership: 0.042%View All Insider TransactionsView All Institutional Transactions ELYM Stock Analysis - Frequently Asked Questions How have ELYM shares performed this year? Eliem Therapeutics' stock was trading at $2.70 at the beginning of the year. Since then, ELYM shares have increased by 191.1% and is now trading at $7.86. View the best growth stocks for 2024 here. How were Eliem Therapeutics' earnings last quarter? Eliem Therapeutics, Inc. (NASDAQ:ELYM) released its earnings results on Wednesday, August, 14th. The company reported ($1.81) earnings per share (EPS) for the quarter. When did Eliem Therapeutics IPO? Eliem Therapeutics (ELYM) raised $75 million in an IPO on Tuesday, August 10th 2021. The company issued 6,000,000 shares at a price of $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities acted as the underwriters for the IPO. Who are Eliem Therapeutics' major shareholders? Eliem Therapeutics' top institutional shareholders include Affinity Asset Advisors LLC (5.62%), Driehaus Capital Management LLC (2.34%), Ally Bridge Group NY LLC (1.68%) and Renaissance Technologies LLC (0.12%). Insiders that own company stock include Ra Capital Management, LP, Valerie Morisset and Emily Pimblett. View institutional ownership trends. How do I buy shares of Eliem Therapeutics? Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELYM) was last updated on 9/9/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredWall Street Insider Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
